Comparative Evaluation of Nebulized 3% Hypertonic Saline and Nebulized Adrenaline in the Management of Acute Bronchiolitis in Pediatric Patients: A Prospective Hospital-Based Study
International Journal of Pharmaceutical Quality Assurance · 30.06.2026 · 17 (06)
DOI: 10.25258/ijpqa.17.6.22 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmaceutical Quality Assurance, online erschienen am 30.06.2026. Verfasst von Drashti Agnihotri und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Acute bronchiolitis is the most common lower respiratory tract infection among infants and children younger than two years of age and remains a major cause of hospitalization worldwide. The disease is characterized by inflammation, edema, necrosis of epithelial cells lining the small airways, and increased mucus production, resulting in airway obstruction and respiratory distress. Respiratory Syncytial Virus (RSV) is the most frequently implicated pathogen, accounting for approximately 60–80% of cases. Although supportive care remains the cornerstone of treatment, nebulized therapies such as hypertonic saline and adrenaline are widely used to improve clinical outcomes.
Aim
To compare the efficacy and duration of hospitalization associated with nebulized 3% hypertonic saline and nebulized adrenaline in pediatric patients suffering from acute bronchiolitis. Materials and Methods: A prospective observational study was conducted in the Departments of Pharmacology and Pediatrics at Muzaffarnagar Medical College and Hospital, Uttar Pradesh. A total of 100 children aged 3 months to 3 years diagnosed with acute bronchiolitis were enrolled. Fifty patients received nebulized 3% hypertonic saline and fifty received nebulized adrenaline. Clinical severity was assessed using the Wang Bronchiolitis. Statistical analysis was performed using SPSS version 29.
Results
Among the enrolled patients, 96 completed the study. Hypertonic saline therapy resulted in significantly greater improvement in respiratory rate scores, wheezing scores, chest retraction scores, and general appearance scores compared to adrenaline therapy. By Day 3, respiratory rate scores decreased from 2.22±0.61 to 1.34±0.47 in the hypertonic saline group compared with 2.44±0.67 to 1.80±0.53 in the adrenaline group. Wheezing scores declined significantly by Day 3 (0.92±0.27 vs 1.31±0.27, p
Zitieren
APA
Agnihotri, D., Suman, A., Gupta, N., Ranjan, A., Bhargava, V., Gupta, S., Cheema, A. S., Verma, H., Balothiya, H. V., Gaur, A., & Malik, P. (2026). Comparative Evaluation of Nebulized 3% Hypertonic Saline and Nebulized Adrenaline in the Management of Acute Bronchiolitis in Pediatric Patients: A Prospective Hospital-Based Study. International Journal of Pharmaceutical Quality Assurance, 17(06). https://doi.org/10.25258/ijpqa.17.6.22
Vancouver
Agnihotri D, Suman A, Gupta N, Ranjan A, Bhargava V, Gupta S, et al. Comparative Evaluation of Nebulized 3% Hypertonic Saline and Nebulized Adrenaline in the Management of Acute Bronchiolitis in Pediatric Patients: A Prospective Hospital-Based Study. International Journal of Pharmaceutical Quality Assurance. 2026;17(06). doi:10.25258/ijpqa.17.6.22
BibTeX
@article{Agnihotri2026,
author = {Agnihotri, Drashti and Suman, Akanksha and Gupta, Neetu and Ranjan, Amritesh and Bhargava, Vinish and Gupta, Sonal and Cheema, Arshdeep Singh and Verma, Himanshu and Balothiya, Harsh Vardhan and Gaur, Akansha and Malik, Prashant},
title = {Comparative Evaluation of Nebulized 3% Hypertonic Saline and Nebulized Adrenaline in the Management of Acute Bronchiolitis in Pediatric Patients: A Prospective Hospital-Based Study},
journal = {International Journal of Pharmaceutical Quality Assurance},
year = {2026},
volume = {17},
number = {06},
doi = {10.25258/ijpqa.17.6.22}
}
EUVIMED